1. Home
  2. URG vs CRMD Comparison

URG vs CRMD Comparison

Compare URG & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.62

Market Cap

594.4M

ML Signal

HOLD

Logo CorMedix Inc.

CRMD

CorMedix Inc.

HOLD

Current Price

$7.01

Market Cap

605.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
CRMD
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
594.4M
605.9M
IPO Year
2006
2009

Fundamental Metrics

Financial Performance
Metric
URG
CRMD
Price
$1.62
$7.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$2.52
$15.29
AVG Volume (30 Days)
8.9M
1.9M
Earning Date
01-01-0001
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
67.03
EPS
N/A
1.97
Revenue
$33,706,000.00
$43,472,170.00
Revenue This Year
N/A
$627.64
Revenue Next Year
$183.54
N/A
P/E Ratio
N/A
$3.57
Revenue Growth
90.66
66363.08
52 Week Low
$0.55
$5.60
52 Week High
$2.35
$17.43

Technical Indicators

Market Signals
Indicator
URG
CRMD
Relative Strength Index (RSI) 48.55 34.86
Support Level $1.54 $7.29
Resistance Level $1.71 $7.74
Average True Range (ATR) 0.11 0.32
MACD -0.02 0.05
Stochastic Oscillator 37.66 1.99

Price Performance

Historical Comparison
URG
CRMD

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Share on Social Networks: